Pacific Biosciences of California (PACB) Stock Price, News & Analysis

Company Overview

Pacific Biosciences of California, Inc. (NASDAQ: PACB) develops and commercializes life-science technologies for DNA sequencing. The company is best known for its Single Molecule, Real-Time (SMRT) sequencing platform, which produces highly accurate, long-read sequencing data used to study genomes, transcriptomes and other biological systems.

PacBio’s product portfolio includes the Revio and Sequel IIe long-read sequencing systems, associated consumables and sample-preparation solutions, and software for data analysis and interpretation. Its HiFi sequencing technology is designed to generate accurate long reads that can help researchers identify complex genetic variations, assemble genomes and support applications in biomedical research, population genomics, agriculture and other fields. The company also offers the Onso sequencing platform, a short-read system developed through its acquisition of Omniome.

Founded in 2004, PacBio serves academic, government, pharmaceutical, biotechnology, clinical and agricultural customers in the United States and international markets. The company is headquartered in Menlo Park, California, and is led by Chief Executive Officer Christian Henry.

Key Stats

• Today's Range: $1.34 to $1.40
• 50-Day Range: $1.11 to $1.56
• 52-Week Range: $1.07 to $2.73
• Volume: 4.91 million shs
• Average Volume: 5.65 million shs
• Market Capitalization: $425.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.71
• Consensus Rating: Reduce

Pacific Biosciences of California Stock Analysis - MarketRank™

Pacific Biosciences of California scored higher than 47% of companies evaluated by MarketBeat, and ranked 529th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Reduce

Consensus Rating

Pacific Biosciences of California has received a consensus rating of Reduce. The company's average rating score is 1.83, and is based on no strong buy ratings, 1 buy rating, 3 hold ratings, and 2 sell ratings.

Upside Potential

Pacific Biosciences of California has a consensus price target of $1.71, representing about 25.0% upside from its current price of $1.37.

Amount of Analyst Coverage

Pacific Biosciences of California has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Pacific Biosciences of California are expected to grow in the coming year, from ($0.52) to ($0.48) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pacific Biosciences of California is -3.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pacific Biosciences of California is -3.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pacific Biosciences of California has a P/B Ratio of 68.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

16.56% of the float of Pacific Biosciences of California has been sold short.

Short Interest Ratio / Days to Cover

Pacific Biosciences of California has a short interest ratio ("days to cover") of 6.75.

Change versus previous month

Short interest in Pacific Biosciences of California has recently decreased by 7.18%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pacific Biosciences of California does not currently pay a dividend.

Dividend Growth

Pacific Biosciences of California does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.51

News Sentiment

Pacific Biosciences of California has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Pacific Biosciences of California this week, compared to 3 articles on an average week.

Search Interest

Only 5 people have searched for PACB on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

MarketBeat Follows

7 people have added Pacific Biosciences of California to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Pacific Biosciences of California insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,409.00 in company stock.

Percentage Held by Insiders

3.70% of the stock of Pacific Biosciences of California is held by insiders.

Percentage Held by Institutions

Pacific Biosciences of California has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/03/2026
• Today: 9/19/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:PACB
• CIK: 1299130
• Web: www.pacb.com
• Phone: (650) 521-8000
• Fax: 302-636-5454
• Employees: 485
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Pacific Biosciences of California: $1.71
• High Price Target: $2.00
• Low Price Target: $1.35
• Potential Upside/Downside: +25.0%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$546.38 million
• Net Margins: -82.49%
• Pretax Margin: -81.97%
• Return on Equity: -5,752.12%
• Return on Assets: -19.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.92
• Quick Ratio: 4.03

Sales & Book Value

• Annual Sales: $160.01 million
• Price / Sales: 2.66
• Cash Flow: $0.79 per share
• Price / Cash Flow: 1.74
• Book Value: $0.02 per share
• Price / Book: 68.50

Miscellaneous

• Outstanding Shares: 310,830,000
• Free Float: 299,330,000
• Market Cap: $425.84 million
• Optionable: Optionable
• Beta: 2.31